Literature DB >> 6728365

Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study.

R C Boronow, C P Morrow, W T Creasman, P J Disaia, S G Silverberg, A Miller, J A Blessing.   

Abstract

The pathologic features of a prospective study of FIGO stage I endometrial cancer is presented. The uterus, tubes, ovaries, and pelvic lymph nodes of 222 cases and aortic nodes of 157 cases have been analyzed. The surgical-pathologic specimen would suggest a negligible risk for lymph node metastasis if: cancer is confined to the endometrium irrespective of grade, invasion is superficial for grades 1 and 2 tumor, the intermediate third of the myometrium is invaded for grade 1 tumor only, and occult disease is not present in the cervix and/or adnexa. Conversely, a substantial risk for lymph node metastasis exists if the surgical-pathologic study identifies superficial myometrial invasion by grade 3 cancer, intermediate myometrial invasion by grade 2 or 3 cancer, deep myometrial invasion by cancer of any grade, vascular space involvement, and extension of tumor to the cervix and/or adnexa.

Entities:  

Mesh:

Year:  1984        PMID: 6728365

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  69 in total

1.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma.

Authors:  Nora T Kizer; Feng Gao; Saketh Guntupalli; Premal H Thaker; Matthew A Powell; Paul J Goodfellow; David G Mutch; Israel Zighelboim
Journal:  Ann Surg Oncol       Date:  2010-12-22       Impact factor: 5.344

3.  How often does cervical involvement upstage patients with non-myoinvasive (otherwise stage 1A) endometrioid adenocarcinoma of the endometrium?

Authors:  Oluwole Fadare; Laurephile Desrosiers; Zhefu F Xiao; Sa A Wang
Journal:  Virchows Arch       Date:  2007-04-04       Impact factor: 4.064

4.  Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging.

Authors:  K Kinkel; R Forstner; F M Danza; L Oleaga; T M Cunha; A Bergman; J O Barentsz; C Balleyguier; B Brkljacic; J A Spencer
Journal:  Eur Radiol       Date:  2009-02-05       Impact factor: 5.315

5.  Comprehensive surgical staging for endometrial cancer.

Authors:  Bunja Rungruang; Alexander B Olawaiye
Journal:  Rev Obstet Gynecol       Date:  2012

Review 6.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

7.  Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer.

Authors:  Hyun Hoon Chung; Gi Jeong Cheon; Hee Seung Kim; Jae Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

8.  How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.

Authors:  Sokbom Kang; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Chan-Yong Park; Ki-Tae Kim
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

9.  Recurrence and survival in surgically treated endometrioid endometrial cancer.

Authors:  Alex Sanjuán; Teresa Cobo; Georgia Escaramís; Angels Rovirosa; Jaume Ordi; Sonia García; Sandra Hernández; Xavier Caparrós; Aureli Torné; Sergio Martínez Román; Juan Antonio Lejárcegui; Jaume Pahisa
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

Review 10.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

Authors:  L-C Horn; K Schierle; D Schmidt; U Ulrich; A Liebmann; C Wittekind
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.